Fundraising FoxBlueprint Medicines
Cambridge, US · 7 known investors
Find your way into Blueprint Medicines
Sign up to see every warm intro you have to Blueprint Medicines
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Blueprint Medicines team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Blueprint Medicines is a biopharmaceutical company that discovers and develops targeted medicines for patients with diseases such as gastrointestinal stromal tumor and other conditions driven by genetic changes. It markets approved therapies internationally and runs patient access programs across multiple countries.
Founders & leadership
Board
Investors · 7
How we know: F-Prime Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Foresite Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Nextech Invest's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: RA Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Ridgeback Capital's portfolio page · Not right? Tell us
Funding
SEC filings, press & company announcements$73.2M disclosed across 2 of 3 rounds · 2014–2026
- Undisclosed amountSeries CMar 2026Source ↗
▶$50MraisedNov 2014 · 29 investors · BiotechnologyRule 506(b)
- Alexis BorisyDirector
- Nicholas LydonDirector
- Jeffrey W. AlbersExecutive Officer, Director
- Kyle KuvalankaExecutive Officer
- Stephen KnightDirector
- Thilo SchroederDirector
- Christoph S. LengauerExecutive Officer
- David SchenkeinDirector
- Daniel LynchDirector
- Christine BellonExecutive Officer
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Nov 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$23.2MraisedJan 2014 · 10 investors · BiotechnologyRule 506(b)
- Alexis BorisyExecutive Officer, Director
- Daniel LynchDirector
- Nick LydonDirector
- David SchenkeinDirector
- Stephen KnightDirector
- Thilo SchroederDirector
- Christoph S. LengauerExecutive Officer
- Christine BellonExecutive Officer
- Kyle KuvalankaExecutive Officer
- Offering amount
- $25.1M
- Amount sold
- $23.2M
- First sale
- Jan 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Blueprint Medicines went on to found or lead other companies.
In the news
Frequently asked questions
- What does Blueprint Medicines do?
- Blueprint Medicines is a biopharmaceutical company that discovers and develops targeted medicines for patients with diseases such as gastrointestinal stromal tumor and other conditions driven by genetic changes. It markets approved therapies internationally and runs patient access programs across multiple countries.
- Who founded Blueprint Medicines?
- Blueprint Medicines was founded by Nick Lydon, Christoph S. Lengauer.
- Who are Blueprint Medicines's investors?
- Blueprint Medicines's investors include F-Prime Capital, Foresite Capital, Nextech Invest, RA Capital, Ridgeback Capital, Wellington Management, Third Rock Ventures.
- How much funding has Blueprint Medicines raised?
- Blueprint Medicines has disclosed $73.2M raised across 2 of its 3 known rounds.
- Where is Blueprint Medicines headquartered?
- Blueprint Medicines is headquartered in Cambridge, US.